

AGENDA ITEM

(3.5)

POPULATION HEALTH & PARTNERSHIPS COMMITTEE
Pharmaceutical Needs Assessment (PNA) Update

Date of meeting	(07/04/2021)
FOI Status	Open/Public
If closed please indicate reason	Choose an item.
Prepared by	Brian Hawkins Deputy Clinical Director, Medicines Management
Presented by	Julie Denley Director of Primary Care & Mental Health
Approving Executive Sponsor	Executive Medical Director
Report purpose	FOR NOTING

Engagement (internal/external) undertaken to date (including receipt/consideration at Committee/group)

Committee/Group/Individuals	Date	Outcome
PNA Steering Group	29/03/21	SUPPORTED

ACRONYMS

PNA	Pharmaceutical needs assessment
LMC	Local Medical Committee
CTMUHB	Cwm Taf Morgannwg University Health Board

1. SITUATION/BACKGROUND

1.1 Welsh Government has changed the way in which applications from pharmacies, dispensing appliance contractors and dispensing doctors to

provide pharmaceutical services are made and determined by introducing pharmaceutical needs assessments or PNAs.

1.2 The NHS (Pharmaceutical Services) (Wales) Regulations 2020, which introduce PNA in Wales, came into force on 1st October 2020 and place a statutory duty on each health board to publish its first PNA by 1st October 2021. As a result, CTMUHB has begun the process of developing its first PNA.

1.3 From 1st October 2021, Health Boards will need to use the published PNA when determining applications from pharmacies, dispensing appliance contractors and dispensing doctors to provide pharmaceutical services under these regulations.

1.4 The PNA will:

- Look at the health needs of CTMUHB's resident population and those who may be temporarily in its area, both now and in the five year lifespan of the PNA;
- Look at how the provision of pharmaceutical services can meet those health needs;
- Map the provision of pharmaceutical services within the Health Board's area;
- Identify the provision of pharmaceutical services outside CTM's area for example elsewhere in Wales and also in England;
- Identify any gaps in the provision of pharmaceutical services now and in the lifespan of the PNA; and
- Turn those gaps into current and future needs for pharmaceutical services.

1.5 Once the PNA is published, it will be used by CTMUHB to determine applications from pharmacies and dispensing appliance contractors who wish to open new premises or relocate existing premises. It will also be used to determine outline consent and premises approval applications from dispensing doctors.

1.6 The following services fall within the legal definition of pharmaceutical services:

- Essential, advanced and enhanced services provided by pharmacies and dispensing appliance contractors, and
- The dispensing service provided by some GP practices.

In addition, the PNA will also include services provided by other providers for example hospital and prison pharmacies.

1.7 **Steering Group**



CTMUHB has set up a PNA Steering Group which will oversee the drafting of the PNA and is being supported by PCC CIC (PCC CIC are a company that has experience of drafting PNAs and assisted in the drafting of the Welsh regulations) they will be responsible for drafting the PNA. The group was established in November 2020 and plans to meet on a quarterly basis but more frequently if required.

The purpose of the group is to develop and agree content of a robust pharmaceutical needs assessment that complies with the requirements of the National Health Service (Pharmaceutical Services) (Wales) Regulations 2020 and the needs of the local population. The PNA will also provide an evidence base for future local commissioning intentions.

The Chair of this Steering Group is the Director of Primary Care, Community and Mental Health and the members are representatives from Primary Care, Pharmacy, Public Health, LMC, Communications team, Finance, Planning, CHC and Community Pharmacy Wales also Pharmacy project management support. The Steering Group will be accountable to the Primary Care Community & Health Partnership Committee. Its primary role is to advise and develop structures and processes to support the preparation of a comprehensive, well-researched, well-considered and robust PNA, building on expertise from across the local healthcare community.

2. SPECIFIC MATTERS FOR CONSIDERATION BY THIS MEETING (ASSESSMENT)

2.1 Process Update

A public/patient survey was circulated to the UHB population at the end of December to mid-January and this received 637 responses which are currently being analysed. Also, as part of this process all Community Pharmacies have been consulted across Wales and this has resulted in 100% response rate.

2.2 The risk throughout this process is not having a robust and approved draft PNA for 60 day consultation and thereafter final sign-off in a timely manner in order to achieve the end date. A submission to the risk register to identify actions to mitigate this is being agreed and the Executive lead has been identified. The Steering Group has received a project plan (appendix 1) which is regularly updated throughout the project to ensure the final report is ready for publication in the agreed timeframe.

2.3 The draft PNA is being presented to the Steering Group on 29 March and then to Management Board on Wednesday 21 April. Public consultation will be for 60 days in May and June then the final report will be presented to the Management Board on Wednesday 22 September. The final approved document will be published by 1 October 2021.



3. KEY RISKS/MATTERS FOR ESCALATION TO BOARD/COMMITTEE

3.1 Meeting the statutory publication timescales will be challenging, the project is currently progressing to plan.

3.2 A project manager has been key in progressing this work to date and it is proposed to continue this post until the PNA is published. This has been highlighted as a cost pressure for Medicines Management in the 2021/2022 IMTP.

4. IMPACT ASSESSMENT

Quality/Safety/Patient Experience implications	Yes (Please see detail below)
	The new PNA regulations will change fundamentally how the community pharmacy Control of Entry decisions are made - by shifting from a system that is driven by the contractors and focused heavily on dispensing - to a system led by the NHS that responds to the wider pharmaceutical needs of local communities. This approach should improve access to care, widen the enhanced services provided by community pharmacies and support the inverse care principles of targeting health care provision where there is the greatest need.
Related Health and Care standard(s)	Safe Care
	Also: Staying healthy Effective Care Timely Care Individual Care
Equality impact assessment completed	Yes
	The PNA will need to incorporate the provision of the Equality Act 2010 to ensure that the assessment of pharmaceutical need considers the protected characteristics under the Act.



Legal implications / impact	Yes (Include further detail below)
	The Public Health (Wales) Act 2017, given Royal Assent on 3 July 2017, places an obligation upon health boards to undertake a pharmaceutical needs assessment (PNA). The regulations which came into force in October 2020 make it a legal requirement for Health Boards to complete and publish a pharmaceutical needs assessment (PNA) by 1 October 2021.
Resource (Capital/Revenue £/Workforce) implications / Impact	Yes (Include further detail below)
	There are potential financial risks of funding additional pharmaceutical contracts if gaps in pharmaceutical need are identified. This will form part of the Health Board planning process and be included in the IMTP if necessary. Continuing the project management to deliver the PNA will be a cost pressure in 2021/2022
Link to Strategic Well-being Objectives	Work with communities and partners to reduce inequality, promote well-being and prevent ill-health

5. RECOMMENDATION

- 5.1 The Committee is asked to:
- 5.2 Support the PNA steering group in achieving the target date for publication by 1 October 2021.
- 5.3 Recommend that guidance is provided, where requested, and papers are reviewed by various identified committees for sign-off within the process. The final PNA publication will be signed by CTMUHB Management Board.